Alnylam Pharmaceuticals annual working capital
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Alnylam Pharmaceuticals Working Capital Growth & History (ALNY)
Alnylam Pharmaceuticals's working capital was $2.58B for fiscal 2025.
View full Alnylam Pharmaceuticals company overviewAlnylam Pharmaceuticals annual working capital history
| Fiscal year | Period ended | Working capital | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $2.58B | $475.3M | +22.54% |
| 2024 | 2024-12-31 | $2.11B | $94.1M | +4.67% |
| 2023 | 2023-12-31 | $2.01B | $90.6M | +4.71% |
| 2022 | 2022-12-31 | $1.92B | −$188.5M | −8.92% |
| 2021 | 2021-12-31 | $2.11B | $83.4M | +4.11% |
| 2020 | 2020-12-31 | $2.03B | $666.2M | +48.87% |
| 2019 | 2019-12-31 | $1.36B | $342.1M | +33.50% |
| 2018 | 2018-12-31 | $1.02B | −$599.3M | −36.98% |
| 2017 | 2017-12-31 | $1.62B | $1.08B | +199.99% |
| 2016 | 2016-12-31 | $540.2M | −$503.1M | −48.22% |
| 2015 | 2015-12-31 | $1.04B | $392.3M | +60.25% |
| 2014 | 2014-12-31 | $651.0M | $450.9M | +225.25% |
| 2013 | 2013-12-31 | $200.2M | $123.0M | +159.24% |
| 2012 | 2012-12-31 | $77.2M | $6.2M | +8.69% |
| 2011 | 2011-12-31 | $71.0M | −$81.1M | −53.29% |
| 2010 | 2010-12-31 | $152.1M | −$30.7M | −16.80% |
| 2009 | 2009-12-31 | $182.8M | — | — |
Alnylam Pharmaceuticals quarterly working capital
Q4.09
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Working capital | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $3.11B | $764.8M | +32.64% |
| Q1 2026 | 2026-03-31 | $2.87B | $677.2M | +30.89% |
| Q4 2025 | 2025-12-31 | $2.58B | $475.3M | +22.54% |
| Q3 2025 | 2025-09-30 | $2.40B | $262.6M | +12.30% |
| Q2 2025 | 2025-06-30 | $2.34B | $225.2M | +10.64% |
| Q1 2025 | 2025-03-31 | $2.19B | $145.7M | +7.12% |
| Q4 2024 | 2024-12-31 | $2.11B | $94.1M | +4.67% |
| Q3 2024 | 2024-09-30 | $2.13B | $99.1M | +4.87% |
| Q2 2024 | 2024-06-30 | $2.12B | $382.2M | +22.02% |
| Q1 2024 | 2024-03-31 | $2.05B | $179.3M | +9.60% |
| Q4 2023 | 2023-12-31 | $2.01B | $90.6M | +4.71% |
| Q3 2023 | 2023-09-30 | $2.04B | $117.6M | +6.13% |
| Q2 2023 | 2023-06-30 | $1.74B | −$78.5M | −4.33% |
| Q1 2023 | 2023-03-31 | $1.87B | −$116.1M | −5.85% |
| Q4 2022 | 2022-12-31 | $1.92B | −$188.5M | −8.92% |
| Q3 2022 | 2022-09-30 | $1.92B | −$146.7M | −7.10% |
| Q2 2022 | 2022-06-30 | $1.81B | −$356.6M | −16.43% |
| Q1 2022 | 2022-03-31 | $1.98B | $8.5M | +0.43% |
| Q4 2021 | 2021-12-31 | $2.11B | $83.4M | +4.11% |
| Q3 2021 | 2021-09-30 | $2.06B | −$9.8M | −0.47% |
| Q2 2021 | 2021-06-30 | $2.17B | $394.4M | +22.20% |
| Q1 2021 | 2021-03-31 | $1.98B | $729.3M | +58.53% |
| Q4 2020 | 2020-12-31 | $2.03B | $666.2M | +48.87% |
| Q3 2020 | 2020-09-30 | $2.07B | $530.1M | +34.32% |
| Q2 2020 | 2020-06-30 | $1.78B | $41.0M | +2.36% |
| Q1 2020 | 2020-03-31 | $1.25B | $3.1M | +0.25% |
| Q4 2019 | 2019-12-31 | $1.36B | $342.1M | +33.50% |
| Q3 2019 | 2019-09-30 | $1.54B | $323.8M | +26.53% |
| Q2 2019 | 2019-06-30 | $1.74B | $346.3M | +24.93% |
| Q1 2019 | 2019-03-31 | $1.24B | −$327.1M | −20.83% |
| Q4 2018 | 2018-12-31 | $1.02B | −$599.3M | −36.98% |
| Q3 2018 | 2018-09-30 | $1.22B | $328.3M | +36.79% |
| Q2 2018 | 2018-06-30 | $1.39B | $536.9M | +63.02% |
| Q1 2018 | 2018-03-31 | $1.57B | $1.07B | +213.10% |
| Q4 2017 | 2017-12-31 | $1.62B | $1.08B | +199.99% |
| Q3 2017 | 2017-09-30 | $892.3M | $226.5M | +34.02% |
| Q2 2017 | 2017-06-30 | $852.0M | $34.5M | +4.22% |
| Q1 2017 | 2017-03-31 | $501.4M | −$482.3M | −49.03% |
| Q4 2016 | 2016-12-31 | $540.2M | −$503.1M | −48.22% |
| Q3 2016 | 2016-09-30 | $665.8M | −$318.9M | −32.38% |
| Q2 2016 | 2016-06-30 | $817.5M | −$145.1M | −15.07% |
| Q1 2016 | 2016-03-31 | $983.7M | −$25.8M | −2.55% |
| Q4 2015 | 2015-12-31 | $1.04B | $392.3M | +60.25% |
| Q3 2015 | 2015-09-30 | $984.7M | $398.5M | +67.99% |
| Q2 2015 | 2015-06-30 | $962.6M | $351.2M | +57.44% |
| Q1 2015 | 2015-03-31 | $1.01B | $419.3M | +71.03% |
| Q4 2014 | 2014-12-31 | $651.0M | $450.9M | +225.25% |
| Q3 2014 | 2014-09-30 | $586.2M | $441.9M | +306.30% |
| Q2 2014 | 2014-06-30 | $611.4M | $450.1M | +279.05% |
| Q1 2014 | 2014-03-31 | $590.2M | $399.9M | +210.06% |
| Q4 2013 | 2013-12-31 | $200.2M | $123.0M | +159.24% |
| Q3 2013 | 2013-09-30 | $144.3M | −$36.9M | −20.37% |
| Q2 2013 | 2013-06-30 | $161.3M | −$22.0M | −12.00% |
| Q1 2013 | 2013-03-31 | $190.4M | $48.5M | +34.15% |
| Q4 2012 | 2012-12-31 | $77.2M | $6.2M | +8.69% |
| Q3 2012 | 2012-09-30 | $181.2M | $95.1M | +110.60% |
| Q2 2012 | 2012-06-30 | $183.3M | $59.5M | +48.04% |
| Q1 2012 | 2012-03-31 | $141.9M | −$9.5M | −6.25% |
| Q4 2011 | 2011-12-31 | $71.0M | −$81.1M | −53.29% |
| Q3 2011 | 2011-09-30 | $86.0M | −$59.2M | −40.75% |
| Q2 2011 | 2011-06-30 | $123.8M | −$47.7M | −27.80% |
| Q1 2011 | 2011-03-31 | $151.4M | — | — |
| Q4 2010 | 2010-12-31 | $152.1M | −$30.7M | −16.80% |
| Q3 2010 | 2010-09-30 | $145.2M | — | — |
| Q2 2010 | 2010-06-30 | $171.5M | — | — |
| Q4 2009 | 2009-12-31 | $182.8M | — | — |
Alnylam Pharmaceuticals working capital trends
Over the last five fiscal years, Alnylam Pharmaceuticals's working capital increased from $2.03B to $2.58B, a change of $554.8M. The latest reported quarter, Q2 2026, shows $3.11B.
About the metric
What working capital means
Working capital is the difference between current assets and current liabilities. It provides a snapshot of short-term operating liquidity, although negative working capital can be normal for some business models and the measure is often not meaningful for banks.
Calculation and source
How working capital is calculated
TickerStat calculates working capital as reported current assets minus reported current liabilities at the same balance-sheet date. Missing current classifications are not assumed to be zero. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Alnylam Pharmaceuticals source filings ↗